The fresh funds will be used to expand clinics, invest in AI-driven healthcare, and enhance patient engagement, strengthening ...
Citizens JMP analyst Reni Benjamin upgraded Allogene Therapeutics (ALLO) to Outperform from Market Perform with a $5 price target The firm ...
TD Cowen analyst Tyler Van Buren maintained a Buy rating on Allogene Therapeutics (ALLO – Research Report) yesterday. The company’s shares ...
Sexual wellness startup Allo Health will use the capital to expand its clinic network, strengthen technological capabilities, ...
SOUTH SAN FRANCISCO, Calif. (AP) — SOUTH SAN FRANCISCO, Calif. (AP) — Allogene Therapeutics Inc. (ALLO) on Thursday reported a loss of $59.9 million in its fourth quarter. On a per-share basis, the ...
March 03, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for ...
Bengaluru-based Allo Health raises INR 16 Cr in Pre-Series A round led by Zerodha's Rainmatter to expand clinic network and ...
Allo Health raises Rs. 16 crore to expand India’s largest sexual health ecosystem: Our Bureau, Bengaluru Wednesday, March 12, 2025, 17:45 Hrs [IST] Allo Health, India’s leadin ...
Sexual health and wellness startup Allo Health has raised Rs 16 crore in a pre-series A round led by Zerodha's Rainmatter, with participation from existing investors. The funds will be used to ...
Key upcoming catalysts include interim data for Cema-cel’s ALPHA3 by mid-2025, and initial trials for ALLO-329 in autoimmune diseases starting in H1, 2025. To date, all commercially available ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback